Navigation Links
China Medical Technologies Announces the Receipt of SFDA Approval for Two of its FISH Probes and the Approval for the Hi-Tech Enterprise Status for its PRC Subsidiaries
Date:1/22/2009

BEIJING, Jan. 22 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Prenatal FISH Probe and Cervical Cancer FISH Probe from the State Food and Drug Administration (the "SFDA") in the People's Republic of China (the "PRC").

The Prenatal FISH Probe is a detection kit for the analysis of trisomies 13, 18 and 21 and sex chromosome aneusomies (X and Y). Prenatal screening of trisomy 21 (Down Syndrome) is becoming more prevalent in China and the Prenatal FISH Probe can provide a quicker and more efficient confirmative approach to the prenatal screening results. The Cervical Cancer FISH Probe is designed to detect the amplification of the TERC gene in human cervical tissue, which has been demonstrated to be associated with the severity of cervical disorders. Detection of the TERC amplification as a biomarker can provide better assessments of cervical disorders for clinical diagnosis.

The Company's PRC subsidiaries have received approval for the hi-tech enterprise status from Beijing government authorities. With this status, the subsidiaries are entitled to a preferential income tax rate of 15% which is lower than the statutory income tax rate of 25%. The status is valid for three years and will be renewed after evaluation by relevant government authorities every three years.

"We are pleased to receive SFDA approval for two of our FISH probes and achieve the hi-tech enterprise status under new stringent criteria," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "With the SFDA approval, our hospital customers in different provinces can apply for the inclusion of the two FISH Probes in the reimbursement menu of respective provincial medical insurance programs which we believe will result in increased usage of the probes in the future. The hi-tech enterprise status demonstrates the government's recognition of our achievements in developing and manufacturing advanced innovative products. Furthermore, the PRC government announced yesterday that an estimated amount of RMB850 billion will be spent in the next three years on healthcare reform initiatives, with a significant portion in medical insurance programs. We believe the IVD industry in China will strongly benefit from these initiatives. As such, we have strong confidence in the Company's future prospects despite the challenging market environment."

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833
     Email: IR@chinameditech.com

'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Pharma Holdings, Inc., Financial Year 2008 Preview
2. Immtech Announces Sale of Property Subsidiary in China
3. Nu Skin Enterprises Receives Broader Direct Selling Authorization in China
4. Shaklee China Opens Beijing Headquarters
5. China Sky One Medical, Inc. Provides Business Update
6. China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers
7. Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China
8. Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference
9. China Medicine Renews Contract with CCG Investor Relations
10. China Nepstar Chain Drugstore Announces New Management Team Members
11. China Nepstar Chain Drugstore Terminates Voting Rights Agreement for Yunnan Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology: